Your browser is no longer supported. Please, upgrade your browser.
AXLA Axcella Health Inc. daily Stock Chart
Axcella Health Inc.
Index- P/E- EPS (ttm)-2.88 Insider Own0.30% Shs Outstand22.22M Perf Week17.69%
Market Cap76.88M Forward P/E- EPS next Y-4.07 Insider Trans288.01% Shs Float16.93M Perf Month5.81%
Income-59.10M PEG- EPS next Q-0.93 Inst Own63.10% Short Float0.67% Perf Quarter-24.45%
Sales- P/S- EPS this Y55.40% Inst Trans- Short Ratio2.53 Perf Half Y-32.16%
Book/sh2.59 P/B1.34 EPS next Y-92.00% ROA-59.50% Target Price14.00 Perf Year-
Cash/sh4.14 P/C0.83 EPS next 5Y- ROE-367.60% 52W Range2.25 - 15.99 Perf YTD-13.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-78.36% Beta-
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low53.78% ATR0.45
Employees64 Current Ratio11.20 Sales Q/Q- Oper. Margin- RSI (14)52.20 Volatility13.04% 17.81%
OptionableNo Debt/Eq0.41 EPS Q/Q67.30% Profit Margin- Rel Volume0.89 Prev Close3.42
ShortableYes LT Debt/Eq0.41 EarningsMar 24 Payout- Avg Volume44.67K Price3.46
Recom1.70 SMA2017.03% SMA50-9.16% SMA200-35.79% Volume41,575 Change1.17%
Jun-03-19Initiated SVB Leerink Outperform $21
Jun-03-19Initiated JP Morgan Overweight $20
Jun-03-19Initiated Goldman Buy $25
Apr-07-20 08:00AM  Axcella Receives Fourth Patent Covering EMM Compositions Business Wire
Mar-30-20 12:00PM  All You Need to Know About Axcella Health Inc. (AXLA) Rating Upgrade to Strong Buy Zacks +30.27%
08:06AM  New Strong Buy Stocks for March 30th Zacks
Mar-23-20 04:01PM  Axcella Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Business Wire -10.00%
Mar-05-20 08:00AM  Axcella Announces Oral Presentation at 2020 International Conference on Frailty and Sarcopenia Research Business Wire
Feb-26-20 07:30AM  Axcella Completes Enrollment of Subjects in AXA1665-002 Study Business Wire -17.84%
Feb-19-20 08:00AM  Axcella to Present at the SVB Leerink 9th Annual Global Healthcare Conference Business Wire
Jan-09-20 08:00AM  Axcella to Present at J.P. Morgan Healthcare Conference Business Wire +8.73%
Jan-08-20 08:00AM  Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones Business Wire +11.98%
Jan-07-20 02:31PM  In first Mass. biotech IPO filing of 2020, cancer startup aims for $100M American City Business Journals
Dec-21-19 03:44PM  Hedge Funds Staying Clear Of Axcella Health Inc. (AXLA) Insider Monkey
Dec-19-19 08:00AM  Flagship Unveils Newest Pioneering Platform: Ring Therapeutics PR Newswire
Dec-07-19 08:00AM  Axcella Presents Data at ASH Annual Meeting Business Wire
Dec-05-19 05:11AM  Trade Alert: The Chairman Of Axcella Health Inc. (NASDAQ:AXLA), David Epstein, Has Just Spent US$54k Buying Shares Simply Wall St.
Nov-25-19 08:00AM  Axcella Strengthens Executive Team with Key Addition and Promotion Business Wire
Nov-20-19 08:00AM  Axcella Announces Issuance of Broad Patent Covering EMM Compositions Business Wire +5.33%
Nov-12-19 04:05PM  Axcella Health Reports Third Quarter 2019 Financial Results and Provides Company Update Business Wire -6.40%
Nov-08-19 08:00AM  Axcella Presents Data at The Liver Meeting Providing New Mechanistic Insights on Observed Multifactorial Effects of its Liver Product Candidates Business Wire -5.46%
Nov-06-19 08:00AM  Axcella Achieves Initial Milestones with its Hematology Product Candidate AXA4010 Business Wire -13.56%
07:08AM  Need To Know: Axcella Health Inc. (NASDAQ:AXLA) Insiders Have Been Buying Shares Simply Wall St.
Oct-23-19 07:30AM  Axcella Enters into Collaboration with CYTOO to Explore Impact of Dysregulated Metabolism on Muscle Physiology Business Wire
Oct-11-19 05:49PM  Bay Area biotech unicorn suffers 5th worst Wall Street debut of year American City Business Journals
Oct-07-19 08:30AM  Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957 Business Wire
Oct-01-19 04:11PM  Axcella Announces Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting Business Wire -6.01%
Sep-03-19 05:45AM  The 4 Worst IPOs So Far This Year
Aug-23-19 04:27PM  Axcella Health Inc. Announces Appointment of Catherine A. Sohn, Pharm. D. to its Board of Directors Business Wire
Aug-12-19 05:06PM  Axcella Health Reports Second Quarter 2019 Financial Results and Provides Company Update Business Wire
Aug-08-19 10:48AM  What Type Of Shareholder Owns Axcella Health Inc.'s (NASDAQ:AXLA)? Simply Wall St.
Aug-07-19 05:54PM  Axcella to Present at the Wedbush PacGrow Healthcare Conference Business Wire
Jul-31-19 08:00AM  Axcella Announces Publication of Data Describing Attenuation of Muscle Atrophy with AXA2678 in Short-Term Muscle Disuse Study Business Wire
Jun-20-19 05:10PM  Axcella Health Reports First Quarter 2019 Financial Results and Provides Company Update GlobeNewswire
May-13-19 05:30PM  Axcella Health Announces Closing of Initial Public Offering GlobeNewswire
May-08-19 08:40PM  Axcella Health Announces Pricing of Initial Public Offering GlobeNewswire
07:11AM  Uber in drivers seat as IPO market gears up for busiest week since 2015 MarketWatch
May-06-19 06:08PM  The Axcella Health IPO: What You Need To Know Benzinga
May-04-19 05:25PM  IPO Outlook For The Week: Uber (And 11 Others) Benzinga
Axcella Health Inc., a biotechnology company, researches and develops novel multifactorial interventions to support health and address dysregulated metabolism in the United States. The company develops its products based on its AXA Development Platform. It offers AXA1665 for use in treating hepatic encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease; AXA2678 for use in treating immobilization-induced acute muscle atrophy; and AXA4010 to target multiple biological pathways. Axcella Health Inc. has a collaboration with CYTOO to explore impact of dysregulated metabolism on muscle physiology. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Epstein David RDirectorFeb 28Buy3.752,0057,51968,103Mar 02 07:04 PM
Epstein David RDirectorFeb 27Buy3.6512,80046,72066,098Mar 02 07:04 PM
Chardonnet LaurentChief Financial OfficerJan 31Buy4.943,00014,8203,665Jan 31 08:44 PM
Chardonnet LaurentChief Financial OfficerJan 27Buy4.943521,739665Jan 28 06:39 PM
Chardonnet LaurentChief Financial OfficerJan 24Buy4.923131,540313Jan 28 06:39 PM
Sohn Catherine A.DirectorJan 17Buy4.871,0004,8701,000Jan 21 04:38 PM
Epstein David RDirectorNov 27Buy3.911,0053,93053,298Dec 02 07:31 PM
Epstein David RDirectorNov 27Buy3.911,0053,93053,298Dec 03 11:20 AM
Epstein David RDirectorNov 26Buy3.5514,00049,70052,293Dec 03 11:20 AM
Epstein David RDirectorNov 26Buy3.5514,00049,70052,293Dec 02 07:31 PM